ANI Pharmaceuticals, Inc. (ANIP)
PHARMACEUTICAL PREPARATIONS
ANI Pharmaceuticals, Inc. (ANIP) is listed on Nasdaq, where it has traded since September 13, 1999.
- Listed On
- Nasdaq
- Listed Since
- September 13, 1999
- Employees
- 970
- Market Cap
- $1.7B
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 294 institutions reported holding ANIP, with 22.9 million shares worth $1.9 billion in aggregate. The largest reported holder was BlackRock, with 3.0 million shares worth $244.9 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| BlackRock | 2,958,646 | $245M | Added 7.69% |
| Vanguard | 1,404,628 | $116M | Added 4.08% |
| Soleus Capital Management | 867,760 | $72M | Added 5.79% |
| State Street | 831,647 | $69M | Added 7.78% |
| Tang Capital Management | 707,500 | $59M | Unchanged |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ANIP?
ANI Pharmaceuticals, Inc. (ANIP) is listed on Nasdaq, where it has traded since September 13, 1999.
Who are the largest institutional holders of ANIP?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ANIP were BlackRock, Vanguard and Soleus Capital Management.
How many institutions own ANIP?
294 institutions reported a position in ANIP for the quarter ended June 30, 2026, worth $1.9 billion in total.
Did institutions buy or sell ANIP last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ANIP.
Every reported institutional holder, plus insider and congressional trades in ANIP, on SentiSense.